Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C

NCT ID: NCT01760187

Last Updated: 2018-11-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-07
• Study Completion Date: 2013-06-03

Brief Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of orally administered lomitapide in healthy male Japanese and Caucasian subjects with elevated LDL-C. The purpose for this study is to evaluate the PK and PD of lomitapide in Japanese subjects as compared to Caucasian subjects.

Conditions

Healthy Volunteer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Cohort 1

12 Japanese and 12 Caucasian subjects. 10 out of 12 will receive 10 mg lomitapide and 2 will receive placebo.

Group Type: EXPERIMENTAL

lomitapide

Intervention Type: DRUG

Cohort 2

8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 20 mg lomitapide and 2 will receive placebo.

Group Type: EXPERIMENTAL

lomitapide

Intervention Type: DRUG

Cohort 3

8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 40 mg lomitapide and 2 will receive placebo.

Group Type: EXPERIMENTAL

lomitapide

Intervention Type: DRUG

Cohort 4

8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 60 mg lomitapide and 2 will receive placebo.

Group Type: EXPERIMENTAL

lomitapide

Intervention Type: DRUG

Interventions

lomitapide

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1. Subject is a healthy male or female, Caucasian or Japanese, aged 20 - 45 years, inclusive, at screening.

2. Subject has a BMI of 18.5 - 30 kg/m2 inclusive at screening.

3. Subjects must have a screening LDL-C measurement and the mean of Day 5 and Day 6 measurements greater than or equal to 110mg/dL.

4. Subjects must agree to use acceptable methods of contraception (details provided in the protocol)

5. Subjects must be capable of understanding and complying with the requirements of the protocol and must have signed the informed consent form prior to undergoing any study-related procedures.

Exclusion Criteria

1. Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion.

2. Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission.

3. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) which in the opinion of the Investigator is clinically relevant or will interfere with the ECG analysis.

4. History or current evidence of any clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological, psychiatric or other disease.

5. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg), anti-Hepatitis core antibody (anti-HBc Ig G [and anti-HBc IgM if IgG is positive], Hepatitis C antibodies (anti-HCV), and HIV 1 and 2 antibodies, (anti-HIV 1/2) at screening.

6. Confirmed positive results from urine drug screen or from the alcohol breath test at screening and on admission (Day -1).

7. History or clinical evidence of alcohol or drug abuse.

8. Mentally handicapped.

9. Participation in a drug trial within 90 days prior to first drug administration.

10. Use of any medication (including over-the-counter (OTC) medication) within 2 weeks prior to admission (Day -1) or within less than 10 times the elimination half-life of the respective drug, or anticipated concomitant medication during the treatment periods.

11. Use of any substance inhibiting CYP3A4 enzymes within 2 weeks prior to admission (Day -1).

12. Donation of more than 500 mL of blood within 90 days prior to drug administration.

13. Subjects who smoke more than 10 cigarettes or equivalent amount of tobacco per day and/or who cannot stop smoking for the duration of the study whilst in the CPU.

14. Treatment with herbal supplements during the 7 days prior to dosing, or use of vitamins during 48 hours prior to admission (Day -1).

15. Any circumstances or conditions, which, in the opinion of the PI, may affect full participation in the trial or compliance with the protocol.

16. Legal incapacity or limited legal capacity at screening.

17. Subjects who are vegetarians, vegans or have any dietary restrictions conflicting with the study standardised menus.

18. If female, subject was pregnant or lactating (females of child bearing potential must have negative pregnancy tests at screening and admission).

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Richmond Pharmacology Limited

INDUSTRY

Sponsor Role: collaborator

Aegerion Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ulrike Lorch, MD FRCA FFPM

Role: PRINCIPAL_INVESTIGATOR

Richmond Pharmacology Limited

Locations

Richmond Pharmacology Ltd

Croydon, Surrey, United Kingdom

Countries

United Kingdom

Other Identifiers

2012-004220-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

AEGR-733-023

Identifier Type: -

Identifier Source: org_study_id